A Phase 3 interventional study of Herpes Zoster Vaccine GSK1437173A in Herpes Zoster and Herpes Zoster Vaccine, sponsored by GlaxoSmithKline. Completed at 161 sites in 18 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-12.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 6th largest by enrollment, is one of 3 that started in 2016, is one of 22 in phase 3, and was the 18th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 3 started in 2016.
This study's enrollment of 7,539 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 5th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2016, is one of 25 in phase 3, and was the 29th registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was a long-term follow-up of the two studies 110390 and 113077 (ZOSTER-006/022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine and included an assessment of 1 or 2 additional doses in two subgroups of older adults.
This is the long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine and included an assessment of 1 or 2 additional doses on a 0 or 0, 2-month schedule in two subgroups of older adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional inclusion criteria for the 1-Additional Dose Revaccination and Control groups, ONLY:
Female subjects of non- may be enrolled in this study.
Female subjects of childbearing potential may be enrolled in this study, if the subject:
Exclusion Criteria:
Additional exclusion criteria for the 1-Additional Dose Revaccination and Control groups, only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received at least 1 dose of the HZ/su vaccine in the ZOSTER-006/022 primary studies and no additional doses of the HZ/su vaccine in the current ZOSTER-049:EXT 006-022 study were followed up for long-term vaccine efficacy and safety.
Participants who received 2 doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies received 1 additional dose of the HZ/su vaccine at Month 0 in the current ZOSTER-049:EXT 006-022 study.
Biological: Herpes Zoster Vaccine GSK1437173A
Participants who received 2 doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies were revaccinated with 2 additional doses of the HZ/su vaccine at Month 0 and Month 2 in the current ZOSTER-049:EXT 006-022 study.
Biological: Herpes Zoster Vaccine GSK1437173A
Participants who received 2 doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and no additional doses of the HZ/su vaccine in the current ZOSTER-049:EXT 006-022 study, but who served as a control for the 2 groups that received 1 or 2 additional doses (1-Additional Dose Group and Revaccination Group).
Intramuscular injection
Number of Participants Having at Least One Confirmed Herpes Zoster (HZ) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall
A suspected case of HZ is defined as a new unilateral rash accompanied by pain and no alternative diagnosis. A confirmed case of HZ was diagnosed by Polymerase Chain Reaction (PCR) and/or by HZ Ascertainment Committee (HZAC) determination, as per the algorithm pre-specified in the protocol. As pre-specified in the protocol: * due to the high VE observed in ZOSTER-006/022 studies, recipients of placebo in both studies were offered cross-vaccination with HZ/su. Since there was no placebo group in this study, historic controls were used for VE assessment. Incidence rates estimations on Historical Control group were done by utilizing Poisson regression model using placebo data from ZOSTER-006/022 studies to obtain the coefficients by age ranges. * the participants in Control group were a subset of LTFU group that were randomized to serve as control for those who were vaccinated in this study, otherwise they were treated similarly as LTFU group, hence LTFU and Control groups were combined.
Time frame: During the total duration of ZOSTER-049:EXT 006-022 study (From Month 0 to Month 72)
Number of Participants Having at Least One Confirmed HZ Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, by Age Ranges
A suspected case of HZ is defined as a new unilateral rash accompanied by pain and no alternative diagnosis. A confirmed case of HZ was diagnosed by PCR and/or by the HZAC determination, as per the algorithm pre-specified in the protocol. The age ranges assessed were: 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.
Time frame: During the total duration of ZOSTER-049:EXT 006-022 study (From Month 0 to Month 72)
Number of Participants Having at Least One Confirmed HZ Case From One Month Post-Dose 2 in ZOSTER-006/022 Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges
A suspected case of HZ is defined as a new unilateral rash accompanied by pain and no alternative diagnosis. A confirmed case of HZ was diagnosed by PCR and/or by the HZAC determination, as per the algorithm pre-specified in the protocol. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies. As pre-specified in the protocol: \- participants from the Placebo groups in the ZOSTER-006/022 studies for Year 1 through Year 4 preceding the ZOSTER-049 EXT:006-022 study start and from the hypothetical Historical control group in the ZOSTER-049:EXT 006-022 study for Year 6 and onwards were combined in the Placebo/Historical control group.
Time frame: From one month post-Dose 2 (Month 3) in ZOSTER-006/022 primary studies until the end of ZOSTER-049:EXT 006-022 study (Month 72), a period of approximately 12 years
Number of Participants Having at Least One Confirmed HZ Case Over the Follow-up Years From One Month Post-Dose 2 in ZOSTER-006/022 Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges
A suspected case of HZ is defined as a new unilateral rash accompanied by pain and no alternative diagnosis. A confirmed case of HZ was diagnosed by PCR and/or by the HZAC determination, as per the algorithm pre-specified in the protocol. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies. Confirmed HZ cases data was not collected for the participants included in the HZ/su and Placebo/Historical control groups during Year 5, as this was a gap year between end of ZOSTER-006/-022 studies and start of ZOSTER-049:EXT-006-022 study. Results from the ZOSTER-006/022 studies were pooled for each year after vaccination with methods used in these studies. For overlapping years between ZOSTER-006/022 studies and this study, all the data were pooled. For the non-overlapping years only the data from ZOSTER-049:EXT 006-022 study was used.
Time frame: Over the follow-up years (Year 1, Year 2, Year 3, Year 4, Year 6, Year 7, Year 8, Year 9, Year 10 and Year 11) from one month post-Dose 2 (Month 3) in ZOSTER-006/022 primary studies until the end of ZOSTER-049:EXT 006-022 study (Month 72)
Number of Participants Having at Least One Post-herpetic Neuralgia (PHN) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges
PHN is defined by the presence of HZ-associated severe worst pain persisting or appearing more than 90 days after onset of the HZ rash. Severe worst pain is defined as HZ-associated pain rated as 3 or greater on the worst pain question on the Zoster Brief Pain Inventory (ZBPI) questionnaire. The ZBPI questionnaire uses a 0 to 10 point numeric and visual intensity scale, in which 0 represents the minimum value and 10 the maximum value on the scale. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.
Time frame: During the total duration of ZOSTER-049:EXT 006-022 study (From Month 0 to Month 72)
Number of Participants Having at Least One PHN Case From One Month Post-Dose 2 in ZOSTER-006/022 Primary Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges
PHN is defined by the presence of HZ-associated severe worst pain persisting or appearing more than 90 days after onset of the HZ rash. Severe worst pain is defined as HZ-associated pain rated as 3 or greater on the worst pain question on the Zoster Brief Pain Inventory (ZBPI) questionnaire. The ZBPI questionnaire uses a 0 to 10 point numeric and visual intensity scale, in which 0 represents the minimum value and 10 the maximum value on the scale. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.
Time frame: From one month post-Dose 2 (Month 3) in ZOSTER-006/022 primary studies until the end of ZOSTER-049:EXT 006-022 study (Month 72), a period of approximately 12 years
Number of Participants Having at Least One HZ Related Complications (Other Than PHN) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges
HZ complications include HZ vasculitis, disseminated disease, ophthalmic disease, neurologic disease, visceral disease or stroke. If a recorded complication was associated with a case of suspected HZ, and that case was finally not considered to be a confirmed case, the associated complication would not be considered as a complication of HZ. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.
Time frame: During the total duration of ZOSTER-049:EXT 006-022 study (From Month 0 to Month 72)
Number of Participants Having at Least One HZ Related Complications (Other Than PHN) Case From One Month Post-dose 2 (Month 3) in ZOSTER-006/022 Primary Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges
HZ complications include HZ vasculitis, disseminated disease, ophthalmic disease, neurologic disease, visceral disease or stroke. If a recorded complication was associated with a case of suspected HZ, and that case was finally not considered to be a confirmed case, the associated complication would not be considered as a complication of HZ. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.
Time frame: From one month post-Dose 2 (Month 3) in ZOSTER-006/022 primary studies until the end of ZOSTER-049:EXT 006-022 study (Month 72), a period of approximately 12 years
Anti-glycoprotein (gE) Antibody Concentrations for Humoral Immunity (HI) Subset at Years 5, 6, 7, 8, 9, 10, 11 and 12 After the Primary Vaccination in ZOSTER-006/022 Studies, Overall and by Age Ranges in the LTFU Group
Anti-gE antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs) in milli-international units per milliliter (mIU/mL). The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.
Time frame: At Years 5, 6, 7, 8, 9, 10, 11 and 12 after the primary vaccination in ZOSTER-006/022 studies
Frequency of Antigen-specific CD4 (2+) T-cells for Cell Mediated Immunity (CMI) Subset at Years 5, 6, 7, 8, 9, 10, 11 and 12 After the Primary Vaccination in ZOSTER-006/022 Studies, Overall and by Age Ranges in the LTFU Group
Frequency of CD4 (2+) T-cells with antigen-specific Interferon gamma (IFN-γ) and/or Interleukin-2 (IL-2) and/or Tumour Necrosis Factor alpha (TNF-α) and/or CD40 Ligand (CD40L) secretion/expression to gE was determined by Intracellular Cytokine Staining (ICS) and expressed in CD4 (2+) T-cells/million cells. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.
Time frame: At Years 5, 6, 7, 8, 9, 10, 11 and 12 after the primary vaccination in ZOSTER-006/022 studies
Anti-gE Antibody Concentrations for Participants in LTFU+Control >=50 YOA Group (With a Confirmed HZ Episode) at Years 5, 6, 7, 8, 9, 10, 11 and 12 After the Primary Vaccination in ZOSTER-006/022 Studies
Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in mIU/mL.
Time frame: At Years 5, 6, 7, 8, 9, 10, 11 and 12 after the primary vaccination in ZOSTER-006/022 studies
Frequency of Antigen-specific CD4 (2+) T-cells for Participants in LTFU+Control >=50 YOA Group (With a Confirmed HZ Episode) at Years 5, 6, 7, 8, 9 and 10 After the Primary Vaccination in ZOSTER-006/022 Studies
Frequency of CD4 (2+) T-cells with antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE was determined by ICS and expressed in CD4 (2+) T-cells/million cells.
Time frame: At Years 5, 6, 7, 8, 9, and 10 after the primary vaccination in ZOSTER-006/022 studies
Anti-gE Antibody Concentrations for 1-Additional Dose, Revaccination and Control Groups at Month 1 in the Current ZOSTER-049:EXT 006-022 Study
Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in mIU/mL.
Time frame: At Month 1 in the current ZOSTER-049:EXT 006-022 study
Frequency of Antigen-specific CD4(2+) T-cells for 1-Additional Dose, Revaccination and Control Groups at Month 1 in the Current ZOSTER-049:EXT 006-022 Study
Frequency of CD4 (2+) T-cells with antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE was determined by ICS and expressed in CD4 (2+) T-cells/million cells.
Time frame: At Month 1 in the current ZOSTER-049:EXT 006-022 study
Anti-gE Antibody Concentrations for Revaccination and Control Groups at Month 3 in the Current ZOSTER-049:EXT 006-022 Study
Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in mIU/mL.
Time frame: At Month 3 in the current ZOSTER-049:EXT 006-022 study
Frequency of Antigen-specific CD4 (2+) T-cells for Revaccination and Control Groups at Month 3 in the Current ZOSTER-049:EXT 006-022 Study
Frequency of CD4 (2+) T-cells with antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE was determined by ICS and expressed in CD4 (2+) T-cells/million cells.
Time frame: At Month 3 in the current ZOSTER-049:EXT 006-022 study
Anti-gE Antibody Concentrations for 1 Additional Dose, Revaccination and Control Groups at Month 0 and Years 1, 2, 3, 4, 5 and 6 in the Current ZOSTER-049:EXT 006-022 Study
Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in mIU/mL.
Time frame: At Month 0 and Years 1, 2, 3, 4, 5 and 6 in the current ZOSTER-049:EXT 006-022 study
Frequency of Antigen-specific CD4(2+) T-cells for 1-Additional Dose, Revaccination and Control Groups at Month 0 and Years 1, 2, 3, 4, 5 and 6 in the Current ZOSTER-049:EXT 006-022 Study
Frequency of CD4 (2+) T-cells with antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE was determined by ICS and expressed in CD4 (2+) T-cells/million cells.
Time frame: At Month 0 and Years 1, 2, 3, 4, 5 and 6 in the current ZOSTER-049:EXT 006-022 study
Number of Participants With Any and Grade 3 Solicited Local Symptoms
The assessed solicited local symptoms included pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: Within 7 days after each vaccination (vaccination occurring at Month 0 for 1-Additional Dose Group and at Months 0 and 2 for Revaccination Group) in the current ZOSTER-049:EXT 006-022 study
Duration in Days of Solicited Local Symptoms
Duration is the number of days in which a participant experienced the symptom within the 7-day solicited follow-up period. The assessed solicited local symptoms included pain, redness and swelling.
Time frame: Within 7 days after each vaccination (vaccination occurring at Month 0 for 1-Additional Dose Group and at Months 0 and 2 for Revaccination Group) in the current ZOSTER-049:EXT 006-022 study
Number of Participants With Any, Grade 3 and Related Solicited General Symptoms
The assessed solicited general symptoms included fatigue, fever \[defined as oral temperature \>=37.5 degrees Celsius (°C)\], gastrointestinal symptoms, headache, myalgia, and shivering. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \>39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: Within 7 days after each vaccination (vaccination occurring at Month 0 for 1-Additional Dose Group and at Months 0 and 2 for Revaccination Group) in the current ZOSTER-049:EXT 006-022 study
Duration in Days of Solicited General Symptoms
Duration is the number of days in which a participant experienced the symptom within the 7-day solicited follow-up period. The assessed solicited general symptoms included fatigue, fever \[defined as oral temperature \>=37.5°C\], gastrointestinal symptoms, headache, myalgia, and shivering.
Time frame: Within 7 days after each vaccination (vaccination occurring at Month 0 for 1-Additional Dose Group and at Months 0 and 2 for Revaccination Group) in the current ZOSTER-049:EXT 006-022 study
Number of Participants With Any Unsolicited Adverse Events (AEs)
An unsolicited AE is defined as any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: Within 30 days after any vaccination (vaccination occurring at Month 0 for 1-Additional Dose Group and at Months 0 and 2 for Revaccination Group) in the current ZOSTER-049:EXT 006-022 study
Number of Participants With Any and Related Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant. Any SAE = occurrence of the SAE regardless of intensity or relation to study vaccination. Related SAE = SAE assessed by the investigator as related to vaccination.
Time frame: From Month 0 to Month 12 (1-Additional Dose and Control groups) and from Month 0 until 12 months after last HZ/su vaccination (Revaccination group)
Number of Participants With SAEs Related to Investigational Vaccine, Related to Study Participation or to GSK Concomitant Medication/Vaccine
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant.
Time frame: During the total duration of ZOSTER-049:EXT 006-022 study (from Month 0 to Month 72)
Number of Participants With Any and Related Potential Immune-mediated Diseases (pIMDs)
pIMDs are defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any pIMDs = occurrence of a pIMD regardless of relation to vaccination. Related pIMD = a pIMD assessed by the investigator as related to the study vaccination.
Time frame: From Month 0 to Month 12 (1-Additional Dose and Control groups) and from Month until 12 months after last HZ/su vaccination (Revaccination group)
Potentially eligible participants who participated and received at least one dose of the HZ/su vaccine in the ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies were contacted and considered for entry in the current ZOSTER-049:EXT 006-022 (NCT02723773) study.
| Milestone | LTFU Group | 1-Additional Dose Group | Revaccination Group | Control Group |
|---|---|---|---|---|
| Started | 7289 | 61 | 60 | 119 |
| Completed | 5570 | 52 | 51 | 97 |
| Not completed | 1719 | 9 | 9 | 22 |
| Withdrew: Adverse event | 934 | 3 | 1 | 9 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 360 | 5 | 6 | 10 |
| Withdrew: Migrated/moved from study area | 37 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 198 | 0 | 0 | 0 |
| Withdrew: Other | 189 | 1 | 2 | 2 |
A suspected case of HZ is defined as a new unilateral rash accompanied by pain and no alternative diagnosis. A confirmed case of HZ was diagnosed by Polymerase Chain Reaction (PCR) and/or by HZ Ascertainment Committee (HZAC) determination, as per the algorithm pre-specified in the protocol. As pre-specified in the protocol: * due to the high VE observed in ZOSTER-006/022 studies, recipients of placebo in both studies were offered cross-vaccination with HZ/su. Since there was no placebo group in this study, historic controls were used for VE assessment. Incidence rates estimations on Historical Control group were done by utilizing Poisson regression model using placebo data from ZOSTER-006/022 studies to obtain the coefficients by age ranges. * the participants in Control group were a subset of LTFU group that were randomized to serve as control for those who were vaccinated in this study, otherwise they were treated similarly as LTFU group, hence LTFU and Control groups were combined.
| Participants | LTFU+Control >=50YOA Group | Historical Control >=50 YOA Group |
|---|---|---|
| Number of Participants Having at Least One Confirmed Herpes Zoster (HZ) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall | 69 | 341 |
A suspected case of HZ is defined as a new unilateral rash accompanied by pain and no alternative diagnosis. A confirmed case of HZ was diagnosed by PCR and/or by the HZAC determination, as per the algorithm pre-specified in the protocol. The age ranges assessed were: 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.
| Participants | LTFU+Control 50-59 YOA Group | LTFU+Control 60-69 YOA Group | LTFU+Control >=60 YOA Group | LTFU+Control >=70 YOA Group | Historical Control 50-59 YOA Group | Historical Control 60-69 YOA Group | Historical Control >=60 YOA Group | Historical Control >=70 YOA Group |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Having at Least One Confirmed HZ Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, by Age Ranges | 12 | 9 | 57 | 48 | 90 | 70 | 249 | 179 |
A suspected case of HZ is defined as a new unilateral rash accompanied by pain and no alternative diagnosis. A confirmed case of HZ was diagnosed by PCR and/or by the HZAC determination, as per the algorithm pre-specified in the protocol. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies. As pre-specified in the protocol: \- participants from the Placebo groups in the ZOSTER-006/022 studies for Year 1 through Year 4 preceding the ZOSTER-049 EXT:006-022 study start and from the hypothetical Historical control group in the ZOSTER-049:EXT 006-022 study for Year 6 and onwards were combined in the Placebo/Historical control group.
| Participants | HZ/su >=50 YOA Group | HZ/su 50-59 YOA Group | HZ/su 60-69 YOA Group | HZ/su >=60 YOA Group | HZ/su >=70 YOA Group | Placebo/Historical Control >=50 YOA Group | Placebo/Historical Control 50-59 YOA Group | Placebo/Historical Control 60-69 YOA Group | Placebo/Historical Control >= 60 YOA Group | Placebo/Historical Control >=70 YOA Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Having at Least One Confirmed HZ Case From One Month Post-Dose 2 in ZOSTER-006/022 Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges | 101 | 16 | 12 | 85 | 73 | 818 | 193 | 160 | 623 | 463 |
A suspected case of HZ is defined as a new unilateral rash accompanied by pain and no alternative diagnosis. A confirmed case of HZ was diagnosed by PCR and/or by the HZAC determination, as per the algorithm pre-specified in the protocol. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies. Confirmed HZ cases data was not collected for the participants included in the HZ/su and Placebo/Historical control groups during Year 5, as this was a gap year between end of ZOSTER-006/-022 studies and start of ZOSTER-049:EXT-006-022 study. Results from the ZOSTER-006/022 studies were pooled for each year after vaccination with methods used in these studies. For overlapping years between ZOSTER-006/022 studies and this study, all the data were pooled. For the non-overlapping years only the data from ZOSTER-049:EXT 006-022 study was used.
| Participants | HZ/su >=50 YOA Group | HZ/su 50-59 YOA Group | HZ/su 60-69 YOA Group | HZ/su >=60 YOA Group | HZ/su >=70 YOA Group | Placebo/Historical Control >=50 YOA Group | Placebo/Historical Control 50-59 YOA Group | Placebo/Historical Control 60-69 YOA Group | Placebo/Historical Control >= 60 YOA Group | Placebo/Historical Control >=70 YOA Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Year 1 | 3 | 1 | 0 | 2 | 2 | 130 | 31 | 16 | 99 | 83 |
| Year 2 | 10 | 2 | 1 | 8 | 7 | 136 | 27 | 22 | 109 | 87 |
| Year 3 | 9 | 0 | 0 | 9 | 9 | 116 | 29 | 29 | 87 | 58 |
| Year 4 | 10 | 1 | 2 | 9 | 7 | 95 | 16 | 23 | 79 | 56 |
| Year 6 | 10 | 2 | 1 | 8 | 7 | 62 | 16 | 13 | 47 | 35 |
| Year 7 | 10 | 1 | 2 | 9 | 7 | 61 | 15 | 13 | 46 | 33 |
| Year 8 | 10 | 2 | 2 | 8 | 6 | 58 | 15 | 13 | 43 | 31 |
| Year 9 | 15 | 5 | 3 | 10 | 7 | 57 | 15 | 11 | 42 | 29 |
| Year 10 | 15 | 0 | 1 | 15 | 14 | 53 | 15 | 10 | 38 | 27 |
| Year 11 | 9 | 2 | 0 | 7 | 7 | 50 | 15 | 10 | 34 | 25 |
PHN is defined by the presence of HZ-associated severe worst pain persisting or appearing more than 90 days after onset of the HZ rash. Severe worst pain is defined as HZ-associated pain rated as 3 or greater on the worst pain question on the Zoster Brief Pain Inventory (ZBPI) questionnaire. The ZBPI questionnaire uses a 0 to 10 point numeric and visual intensity scale, in which 0 represents the minimum value and 10 the maximum value on the scale. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.
| Participants | LTFU+Control >=50 YOA Group | LTFU+Control 50-59 YOA Group | LTFU+Control 60-69 YOA Group | LTFU+Control >=60 YOA Group | LTFU+Control >=70 YOA Group | Historical Control >=50 YOA Group | Historical Control 50-59 YOA Group | Historical Control 60-69 YOA Group | Historical Control >=60 YOA Group | Historical Control >=70 YOA Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Having at Least One Post-herpetic Neuralgia (PHN) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges | 4 | 0 | 1 | 4 | 3 | 32 | 7 | 2 | 25 | 23 |
PHN is defined by the presence of HZ-associated severe worst pain persisting or appearing more than 90 days after onset of the HZ rash. Severe worst pain is defined as HZ-associated pain rated as 3 or greater on the worst pain question on the Zoster Brief Pain Inventory (ZBPI) questionnaire. The ZBPI questionnaire uses a 0 to 10 point numeric and visual intensity scale, in which 0 represents the minimum value and 10 the maximum value on the scale. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.
| Participants | HZ/su >=50 YOA Group | HZ/su 50-59 YOA Group | HZ/su 60-69 YOA Group | HZ/su >=60 YOA Group | HZ/su >=70 YOA Group | Placebo/Historical Control >=50 YOA Group | Placebo/Historical Control 50-59 YOA Group | Placebo/Historical Control 60-69 YOA Group | Placebo/Historical Control >= 60 YOA Group | Placebo/Historical Control >=70 YOA Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Having at Least One PHN Case From One Month Post-Dose 2 in ZOSTER-006/022 Primary Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges | 8 | 0 | 1 | 8 | 7 | 78 | 15 | 4 | 63 | 59 |
HZ complications include HZ vasculitis, disseminated disease, ophthalmic disease, neurologic disease, visceral disease or stroke. If a recorded complication was associated with a case of suspected HZ, and that case was finally not considered to be a confirmed case, the associated complication would not be considered as a complication of HZ. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.
| Participants | LTFU+Control >=50 YOA Group | LTFU+Control 50-59 YOA Group | LTFU+Control 60-69 YOA Group | LTFU+Control >=60 YOA Group | LTFU+Control >=70 YOA Group | Historical Control >=50 YOA Group | Historical Control 50-59 YOA Group | Historical Control 60-69 YOA Group | Historical Control >=60 YOA Group | Historical Control >=70 YOA Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Having at Least One HZ Related Complications (Other Than PHN) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges | 1 | 0 | 0 | 1 | 1 | 12 | 0 | 2 | 11 | 9 |
HZ complications include HZ vasculitis, disseminated disease, ophthalmic disease, neurologic disease, visceral disease or stroke. If a recorded complication was associated with a case of suspected HZ, and that case was finally not considered to be a confirmed case, the associated complication would not be considered as a complication of HZ. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.
| Participants | HZ/su >=50 YOA Group | HZ/su 50-59 YOA Group | HZ/su 60-69 YOA Group | HZ/su >=60 YOA Group | HZ/su >=70 YOA Group | Placebo/Historical Control >= 50 YOA Group | Placebo/Historical Control 50-59 YOA Group | Placebo/Historical Control 60-69 YOA Group | Placebo/Historical Control >= 60 YOA Group | Placebo/Historical Control >=70 YOA Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Having at Least One HZ Related Complications (Other Than PHN) Case From One Month Post-dose 2 (Month 3) in ZOSTER-006/022 Primary Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges | 2 | 0 | 0 | 2 | 2 | 28 | 1 | 5 | 26 | 21 |
Anti-gE antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs) in milli-international units per milliliter (mIU/mL). The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.
| mIU/mL | LTFU >=50 YOA Group | LTFU 50-59 YOA Group | LTFU 60-69 YOA Group | LTFU >=60 YOA Group | LTFU >=70 YOA Group |
|---|---|---|---|---|---|
| Year 5 | 8043.5 (7224.9 to 8954.7) | 8044.2 (6106.6 to 10596.6) | 8715.1 (6807.0 to 11158.1) | 8043.2 (7180.7 to 9009.3) | 7868.7 (6915.4 to 8953.5) |
| Year 6 | 8536.6 (8113.5 to 8981.7) | 8584.3 (7739.9 to 9520.7) | 8913.4 (8155.1 to 9742.3) | 8518.3 (8036.5 to 9028.9) | 8258.7 (7646.0 to 8920.4) |
| Year 7 | 8375.1 (7941.0 to 8833.0) | 8325.6 (7483.0 to 9263.1) | 8869.6 (8084.4 to 9731.1) | 8394.8 (7895.3 to 8925.8) | 8080.4 (7446.1 to 8768.7) |
| Year 8 | 8231.2 (7778.2 to 8710.6) | 8318.0 (7412.7 to 9333.9) | 8680.0 (7901.2 to 9535.5) | 8195.4 (7683.4 to 8741.5) | 7856.6 (7193.3 to 8581.0) |
| Year 9 | 7219.4 (6803.4 to 7660.9) | 7097.6 (6341.6 to 7943.7) | 7706.7 (6994.6 to 8491.4) | 7275.0 (6784.2 to 7801.3) | 6951.3 (6295.8 to 7674.9) |
| Year 10 | 6861.5 (6433.2 to 7318.3) | 7007.0 (6228.4 to 7882.9) | 7060.8 (6304.2 to 7908.3) | 6792.5 (6288.2 to 7337.3) | 6574.4 (5913.8 to 7308.8) |
| Year 11 | 7039.3 (6589.0 to 7520.5) | 7146.9 (6294.9 to 8114.3) | 7159.8 (6406.3 to 8001.9) | 6989.2 (6470.8 to 7549.2) | 6846.3 (6148.5 to 7623.3) |
| Year 12 | 6844.3 (6335.2 to 7394.3) | 6737.1 (5900.9 to 7691.7) | 6943.4 (6071.3 to 7940.7) | 6902.0 (6272.0 to 7595.3) | 6848.2 (5976.0 to 7847.6) |
Frequency of CD4 (2+) T-cells with antigen-specific Interferon gamma (IFN-γ) and/or Interleukin-2 (IL-2) and/or Tumour Necrosis Factor alpha (TNF-α) and/or CD40 Ligand (CD40L) secretion/expression to gE was determined by Intracellular Cytokine Staining (ICS) and expressed in CD4 (2+) T-cells/million cells. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.
| CD4 (2+) T-cells/million cells | LTFU >=50 YOA Group | LTFU 50-59 YOA Group | LTFU 60-69 YOA Group | LTFU >=60 YOA Group | LTFU >=70 YOA Group |
|---|---|---|---|---|---|
| Year 5 | 698.00 ± 531.11 | 858.92 ± 639.37 | — | 376.16 ± NA | 376.16 ± NA |
| Year 6 | 886.15 ± 869.09 | 1174.70 ± 1103.76 | 839.31 ± 644.97 | 701.66 ± 621.26 | 474.23 ± 515.96 |
| Year 7 | 859.46 ± 881.80 | 1141.00 ± 1074.96 | 745.36 ± 572.57 | 679.46 ± 683.15 | 577.87 ± 828.60 |
| Year 8 | 896.26 ± 925.58 | 1217.84 ± 1155.53 | 737.78 ± 602.91 | 697.96 ± 688.76 | 629.18 ± 827.35 |
| Year 9 | 1099.20 ± 1151.15 | 1403.78 ± 1435.49 | 930.89 ± 796.20 | 892.09 ± 865.29 | 801.54 ± 1033.67 |
| Year 10 | 1016.13 ± 992.38 | 1210.28 ± 1216.92 | 952.86 ± 763.05 | 865.13 ± 755.35 | 670.87 ± 726.96 |
| Year 11 | 909.95 ± 1025.40 | 1113.90 ± 1317.91 | 884.65 ± 712.45 | 753.74 ± 703.75 | 445.15 ± 597.48 |
| Year 12 | 853.77 ± 815.20 | 1030.37 ± 971.86 | 828.62 ± 666.18 | 715.95 ± 647.90 | 443.65 ± 531.44 |
Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in mIU/mL.
| mIU/mL | LTFU+Control >=50 YOA Group |
|---|---|
| Year 5 | 12455.1 (8549.9 to 18144.1) |
| Year 6 | 8138.7 (5770.6 to 11478.7) |
| Year 7 | 6888.0 (4919.2 to 9644.7) |
| Year 8 | 5831.9 (4435.1 to 7668.6) |
| Year 9 | 7706.8 (5941.6 to 9996.5) |
| Year 10 | 6800.1 (5048.6 to 9159.2) |
| Year 11 | 6214.7 (4807.3 to 8034.2) |
| Year 12 | 4770.7 (3523.6 to 6459.2) |
Frequency of CD4 (2+) T-cells with antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE was determined by ICS and expressed in CD4 (2+) T-cells/million cells.
| CD4 (2+) T-cells/million cells | LTFU+Control >=50 YOA Group |
|---|---|
| Year 5 | 683.76 ± NA |
| Year 6 | 398.70 ± 164.34 |
| Year 7 | 347.43 ± 138.41 |
| Year 8 | 509.67 ± NA |
| Year 10 | 749.75 ± NA |
Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in mIU/mL.
| mIU/mL | 1-Additional Dose Group | Revaccination Group | Control Group |
|---|---|---|---|
| Anti-gE Antibody Concentrations for 1-Additional Dose, Revaccination and Control Groups at Month 1 in the Current ZOSTER-049:EXT 006-022 Study | 73834.4 (60603.6 to 89953.7) | 79419.8 (65089.6 to 96904.9) | 9655.2 (8316.9 to 11208.8) |
Frequency of CD4 (2+) T-cells with antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE was determined by ICS and expressed in CD4 (2+) T-cells/million cells.
| CD4 (2+) T-cells/million cells | 1-Additional Dose Group | Revaccination Group | Control Group |
|---|---|---|---|
| Frequency of Antigen-specific CD4(2+) T-cells for 1-Additional Dose, Revaccination and Control Groups at Month 1 in the Current ZOSTER-049:EXT 006-022 Study | 3899.69 ± 3243.16 | 2803.96 ± 1544.14 | 716.01 ± 635.32 |
Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in mIU/mL.
| mIU/mL | Revaccination Group | Control Group |
|---|---|---|
| Anti-gE Antibody Concentrations for Revaccination and Control Groups at Month 3 in the Current ZOSTER-049:EXT 006-022 Study | 64603.0 (54008.4 to 77275.9) | 9428.1 (8154.4 to 10900.8) |
Frequency of CD4 (2+) T-cells with antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE was determined by ICS and expressed in CD4 (2+) T-cells/million cells.
| CD4 (2+) T-cells/million cells | Revaccination Group | Control Group |
|---|---|---|
| Frequency of Antigen-specific CD4 (2+) T-cells for Revaccination and Control Groups at Month 3 in the Current ZOSTER-049:EXT 006-022 Study | 2443.17 ± 3896.14 | 739.07 ± 659.78 |
Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in mIU/mL.
| mIU/mL | 1-Additional Dose Group | Revaccination Group | Control Group |
|---|---|---|---|
| Month 0 | 10149.5 (8640.2 to 11922.4) | 11548.5 (9386.8 to 14208.0) | 10232.0 (8836.7 to 11847.5) |
| Year 1 | 24663.6 (20790.2 to 29258.7) | 26167.5 (21755.6 to 31474.2) | 8825.4 (7616.3 to 10226.5) |
| Year 2 | 19417.9 (16460.7 to 22906.4) | 19973.2 (16538.1 to 24121.8) | 8643.3 (7450.5 to 10027.0) |
| Year 3 | 16335.6 (13890.4 to 19211.3) | 16264.7 (13417.7 to 19715.7) | 8314.9 (7080.3 to 9764.7) |
| Year 4 | 18676.4 (15562.0 to 22414.2) | 16363.2 (13219.3 to 20254.9) | 8581.7 (7195.2 to 10235.3) |
| Year 5 | 14797.3 (12340.7 to 17742.9) | 14595.7 (11767.0 to 18104.4) | 7238.7 (6004.3 to 8727.0) |
| Year 6 | 12868.4 (11048.3 to 14988.2) | 13534.0 (11107.7 to 16490.2) | 6858.8 (5698.0 to 8256.3) |
Frequency of CD4 (2+) T-cells with antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE was determined by ICS and expressed in CD4 (2+) T-cells/million cells.
| CD4(2+) T-cells/million cells | 1-Additional Dose Group | Revaccination Group | Control Group |
|---|---|---|---|
| Month 0 | 843.55 ± 792.93 | 876.23 ± 784.84 | 817.97 ± 809.77 |
| Year 1 | 1798.39 ± 2119.46 | 1155.04 ± 714.97 | 665.50 ± 603.93 |
| Year 2 | 1634.47 ± 1900.93 | 1154.97 ± 818.16 | 712.02 ± 715.32 |
| Year 3 | 2112.90 ± 2564.29 | 1219.13 ± 889.76 | 836.62 ± 921.57 |
| Year 4 | 2047.92 ± 2477.92 | 1083.64 ± 669.54 | 901.57 ± 917.41 |
| Year 5 | 1649.03 ± 2407.72 | 917.93 ± 648.92 | 720.32 ± 726.20 |
| Year 6 | 1682.94 ± 2694.90 | 844.81 ± 651.28 | 736.01 ± 724.10 |
The assessed solicited local symptoms included pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
| Participants | 1-Additional Dose Group | Revaccination Group |
|---|---|---|
| Any pain, post-Dose 1 | 42 | 52 |
| Grade 3 pain, post-Dose 1 | 1 | 3 |
| Any redness, post-Dose 1 | 13 | 20 |
| Grade 3 redness, post-Dose 1 | 4 | 1 |
| Any swelling, post-Dose 1 | 7 | 12 |
| Grade 3 swelling, post-Dose 1 | 1 | 0 |
| Any pain, post-Dose 2 | — | 37 |
| Grade 3 pain, post-Dose 2 | — | 2 |
| Any redness, post-Dose 2 | — | 20 |
| Grade 3 redness, post-Dose 2 | — | 3 |
| Any swelling, post-Dose 2 | — | 13 |
| Grade 3 swelling, post-Dose 2 | — | 1 |
Duration is the number of days in which a participant experienced the symptom within the 7-day solicited follow-up period. The assessed solicited local symptoms included pain, redness and swelling.
| Days | 1-Additional Dose Group | Revaccination Group |
|---|---|---|
| Pain, post-Dose 1 | 3.0 (2.0 to 3.0) | 3.0 (2.0 to 3.5) |
| Pain, post-Dose 2 | — | 2.0 (2.0 to 3.0) |
| Redness, post-Dose 1 | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 4.0) |
| Redness, post-Dose 2 | — | 2.5 (1.0 to 4.5) |
| Swelling, post-Dose 1 | 2.0 (2.0 to 3.0) | 3.0 (1.0 to 5.0) |
| Swelling, post-Dose 2 | — | 2.0 (1.0 to 3.0) |
The assessed solicited general symptoms included fatigue, fever \[defined as oral temperature \>=37.5 degrees Celsius (°C)\], gastrointestinal symptoms, headache, myalgia, and shivering. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \>39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Participants | 1-Additional Dose Group | Revaccination Group |
|---|---|---|
| Any fatigue, post-Dose 1 | 32 | 24 |
| Grade 3 fatigue, post-Dose 1 | 0 | 2 |
| Related fatigue, post-Dose 1 | 32 | 23 |
| Any fever, post-Dose 1 | 18 | 13 |
| Grade 3 fever, post-Dose 1 | 0 | 0 |
| Related fever, post-Dose 1 | 18 | 13 |
| Any gastrointestinal symptoms, post-Dose 1 | 9 | 9 |
| Grade 3 gastrointestinal symptoms, post-Dose 1 | 0 | 2 |
| Related gastrointestinal symptoms, post-Dose 1 | 9 | 8 |
| Any headache, post-Dose 1 | 23 | 17 |
| Grade 3 headache, post-Dose 1 | 0 | 2 |
| Related headache, post-Dose 1 | 23 | 17 |
| Any myalgia, post-Dose 1 | 27 | 22 |
| Grade 3 myalgia, post-Dose 1 | 0 | 2 |
| Related myalgia, post-Dose 1 | 27 | 21 |
| Any shivering, post-Dose 1 | 25 | 15 |
| Grade 3 shivering, post-Dose 1 | 2 | 4 |
| Related shivering, post-Dose 1 | 25 | 15 |
| Any fatigue, post-Dose 2 | — | 22 |
| Grade 3 fatigue, post-Dose 2 | — | 3 |
| Related fatigue, post-Dose 2 | — | 21 |
| Any fever, post-Dose 2 | — | 7 |
| Grade 3 fever, post-Dose 2 | — | 0 |
| Related fever, post-Dose 2 | — | 4 |
| Any gastrointestinal symptoms, post-Dose 2 | — | 4 |
| Grade 3 gastrointestinal symptoms, post-Dose 2 | — | 0 |
| Related gastrointestinal symptoms, post-dose 2 | — | 4 |
| Any headache, post-Dose 2 | — | 15 |
| Grade 3 headache, post-Dose 2 | — | 1 |
| Related headache, post-Dose 2 | — | 14 |
| Any myalgia, post-Dose 2 | — | 12 |
| Grade 3 myalgia, post-Dose 2 | — | 1 |
| Related myalgia, post-Dose 2 | — | 11 |
| Any shivering, post-Dose 2 | — | 7 |
| Grade 3 shivering, post-Dose 2 | — | 0 |
| Related shivering, post-Dose 2 | — | 7 |
Duration is the number of days in which a participant experienced the symptom within the 7-day solicited follow-up period. The assessed solicited general symptoms included fatigue, fever \[defined as oral temperature \>=37.5°C\], gastrointestinal symptoms, headache, myalgia, and shivering.
| Days | 1-Additional Dose Group | Revaccination Group |
|---|---|---|
| Fatigue, post-Dose 1 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 2.0) |
| Fatigue, post-Dose 2 | — | 2.0 (1.0 to 3.0) |
| Fever, post-Dose 1 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 2.0) |
| Fever, post-Dose 2 | — | 1.0 (1.0 to 2.0) |
| Gastrointestinal symptoms, post-Dose 1 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 3.0) |
| Gastrointestinal symptoms, post-Dose 2 | — | 1.5 (1.0 to 2.0) |
| Headache, post-Dose 1 | 1.0 (1.0 to 2.0) | 2.0 (1.0 to 3.0) |
| Headache, post-Dose 2 | — | 2.0 (1.0 to 3.0) |
| Myalgia, post-Dose 1 | 2.0 (1.0 to 2.0) | 1.0 (1.0 to 3.0) |
| Myalgia, post-Dose 2 | — | 1.5 (1.0 to 2.5) |
| Shivering, post-Dose 1 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) |
| Shivering, post-Dose 2 | — | 1.0 (1.0 to 2.0) |
An unsolicited AE is defined as any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Participants | 1-Additional Dose Group | Revaccination Group |
|---|---|---|
| Number of Participants With Any Unsolicited Adverse Events (AEs) | 13 | 15 |
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant. Any SAE = occurrence of the SAE regardless of intensity or relation to study vaccination. Related SAE = SAE assessed by the investigator as related to vaccination.
| Participants | 1-Additional Dose Group | Revaccination Group | Control Group |
|---|---|---|---|
| Any SAEs | 4 | 4 | 11 |
| Related SAEs | 0 | 0 | 0 |
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant.
| Participants | LTFU Group | 1-Additional Dose Group | Revaccination Group | Control Group |
|---|---|---|---|---|
| Number of Participants With SAEs Related to Investigational Vaccine, Related to Study Participation or to GSK Concomitant Medication/Vaccine | 0 | 0 | 0 | 0 |
pIMDs are defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any pIMDs = occurrence of a pIMD regardless of relation to vaccination. Related pIMD = a pIMD assessed by the investigator as related to the study vaccination.
| Participants | 1-Additional Dose Group | Revaccination Group | Control Group |
|---|---|---|---|
| Any pIMDs | 0 | 0 | 0 |
| Related pIMDs | 0 | 0 | 0 |
Collected over Solicited AEs: Within 7 days after any vaccination & Unsolicited AEs: Within 30 days after any vaccination in this study. All-cause mortality & SAEs related to investigational vaccine/study participation/GSK concomitant medication/vaccine: during the entire study period (Month 0 to Month 72) (all study groups). All SAEs: Month 0 to Month 12 (1-Additional Dose & Control groups) and Month 0 until 12 months after last HZ/su vaccination (Revaccination group).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LTFU Group | 56/7,289 (0.8%) | 62/7,289 (0.9%) | — |
| 1-Additional Dose Group | 0/61 (0%) | 4/61 (6.6%) | 54/61 (88.5%) |
| Revaccination Group | 0/60 (0%) | 4/60 (6.7%) | 58/60 (96.7%) |
| Control Group | 0/119 (0%) | 11/119 (9.2%) | — |
| Event | LTFU Group | 1-Additional Dose Group | Revaccination Group | Control Group |
|---|---|---|---|---|
| SyncopeNervous system disorders | 0/7289 | 0/61 | 1/60 | 2/119 |
| Myocardial infarctionCardiac disorders | 1/7289 | 0/61 | 1/60 | 0/119 |
| Cardiac failure chronicCardiac disorders | 0/7289 | 0/61 | 1/60 | 0/119 |
| DiverticulitisInfections and infestations | 0/7289 | 0/61 | 1/60 | 1/119 |
| Mantle cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/7289 | 0/61 | 1/60 | 0/119 |
| Metastases to peritoneumNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/7289 | 0/61 | 1/60 | 0/119 |
| Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/7289 | 0/61 | 1/60 | 0/119 |
| Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/7289 | 0/61 | 1/60 | 0/119 |
| Acute pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 0/7289 | 0/61 | 1/60 | 0/119 |
| SepsisInfections and infestations | 1/7289 | 1/61 | 0/60 | 0/119 |
| Event | LTFU Group | 1-Additional Dose Group | Revaccination Group | Control Group |
|---|---|---|---|---|
| PainGeneral disorders | — | 42/61 | 53/60 | — |
| FatigueGeneral disorders | — | 32/61 | 33/60 | — |
| ErythemaSkin and subcutaneous tissue disorders | — | 13/61 | 28/60 | — |
| MyalgiaMusculoskeletal and connective tissue disorders | — | 27/61 | 26/60 | — |
| ChillsGeneral disorders | — | 26/61 | 19/60 | — |
| HeadacheNervous system disorders | — | 24/61 | 23/60 | — |
| PyrexiaGeneral disorders | — | 18/61 | 17/60 | — |
| SwellingGeneral disorders | — | 7/61 | 16/60 | — |
| Gastrointestinal disorderGastrointestinal disorders | — | 9/61 | 10/60 | — |
| Oral herpesInfections and infestations | — | 0/61 | 2/60 | — |
| Age, Continuous(Years) | LTFU Group | 1-Additional Dose Group | Revaccination Group | Control Group | Total |
|---|---|---|---|---|---|
| Mean | 72.6 ± 9.4 | 70.4 ± 9.2 | 70.2 ± 9.4 | 70.2 ± 8.6 | 72.5 ± 9.4 |
| Sex: Female, Male(Participants) | LTFU Group | 1-Additional Dose Group | Revaccination Group | Control Group | Total |
|---|---|---|---|---|---|
| Female | 4432 | 30 | 36 | 69 | 4567 |
| Male | 2857 | 31 | 24 | 50 | 2962 |
| Race/Ethnicity, Customized(Participants) | LTFU Group | 1-Additional Dose Group | Revaccination Group | Control Group | Total |
|---|---|---|---|---|---|
| African Heritage / African American | 66 | 0 | 0 | 0 | 66 |
| Asian - East Asian Heritage | 1115 | 0 | 0 | 0 | 1115 |
| Asian - Japanese Heritage | 265 | 0 | 0 | 0 | 265 |
| Other, Deidentified | 5843 | 61 | 60 | 119 | 6083 |
Showing the first 100 of 161 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Apr 2016 to primary completion in Jun 2023, 86 months.
Results were first posted in Sep 2024, 1 year 2 months after primary completion.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 86 months is above that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix